Deerfield Management Company, L.P. (Series C) Alnylam Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 145,000 shares of ALNY stock, worth $34.2 Million. This represents 0.74% of its overall portfolio holdings.
Number of Shares
145,000
Previous 119,800
21.04%
Holding current value
$34.2 Million
Previous $29.1 Million
37.01%
% of portfolio
0.74%
Previous 0.61%
Shares
5 transactions
Others Institutions Holding ALNY
# of Institutions
641Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$3.89 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$2.98 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.25 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.24 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.17 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...